Literature DB >> 19919649

Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.

Enrico Orciuolo, Gabriele Buda, Matteo Pelosini, Mario Petrini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19919649     DOI： 10.1111/j.1365-2141.2009.07998.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

1.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

Review 2.  The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.

Authors:  Richard Arkwright; Tri Minh Pham; Jeffrey A Zonder; Q Ping Dou
Journal:  Expert Opin Drug Discov       Date:  2016-12-20       Impact factor: 6.098

Review 3.  Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.

Authors:  Q Ping Dou; Jeffrey A Zonder
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

Review 4.  Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside.

Authors:  Anthony R Mato; Tatyana Feldman; André Goy
Journal:  Oncologist       Date:  2012-05-07

5.  Ongoing trials in low-grade lymphoma.

Authors:  Alexander Burchardt
Journal:  Hematol Rep       Date:  2011-10-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.